Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2010 1
2011 1
2012 1
2013 2
2014 2
2015 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Effect of dutasteride on the risk of prostate cancer.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group. Andriole GL, et al. N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127. N Engl J Med. 2010. PMID: 20357281 Free article. Clinical Trial.
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Bergmann L, Goebell PJ, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Steiner G, Jakob A, Staehler MD, Steiner T, Overkamp F, Albrecht M, Guderian G, Doehn C. Bergmann L, et al. Among authors: kube u. Onkologie. 2013;36(3):95-100. doi: 10.1159/000348522. Epub 2013 Feb 25. Onkologie. 2013. PMID: 23485996 Free article. Clinical Trial.
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study.
Goebell PJ, Hermann E, Kube U, Doehn C, Marschner N, Dietel A, Blumenstengel K, Grimm MO, Scheffler M, Rogler A, Bergmann L. Goebell PJ, et al. Among authors: kube u. Oncol Res Treat. 2019;42(1-2):57-66. doi: 10.1159/000494278. Epub 2019 Jan 19. Oncol Res Treat. 2019. PMID: 30661070 Free article.
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. Grünwald V, et al. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29. Eur J Cancer. 2012. PMID: 21803569 Clinical Trial.